FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044966413> ?p ?o ?g. }

• W3044966413 endingPage "18886" @default.
• W3044966413 startingPage "18872" @default.
• W3044966413 abstract "The vascular endothelial growth factor receptor 2 (VEGFR2) and c-mesenchymal epithelial transition factor (c-Met) are members of receptor tyrosine kinases which have a crucial role in the process of angiogenesis. Isatin moiety is a versatile group that is shared in many compounds targeting both c-Met and VEGFR2 kinases. In this study, we designed and synthesized different derivatives of substituted 3-(triazolo-thiadiazin-3-yl)indolin-2-one derivatives (6a–y) as dual inhibitors for c-Met and VEGFR2 enzymes. Eight compounds 6a, 6b, 6e, 6l, 6n, 6r, 6v, and 6y were assessed for their anticancer activities against a panel of 58 cancer cell lines according to the US-NCI protocol. Compound 6b revealed the most effective antiproliferative potency (GI %), with broad-spectrum activity against different subpanels of the most NCI 58 tumor cell lines. An in vivo hen’s egg-chorioallantoic membrane (HET-CAM) angiogenic study was carried out for 21 compounds 6a, b, d, f, h, i, k–o, t, and 6x to check their mortality and toxicity. At 100 μM concentration, all compounds produced 100% mortality of the chick embryos. At 40 μM concentration, 13 compounds did not exhibit any detectable mortality (nontoxic) and revealed a potent antiangiogenic effect. Seven compounds 6b, 6d, 6f, 6n, 6o, 6t, and 6x significantly decreased the number of blood vessels, and compound 6b was the most effective antiangiogenic agent comparable to dexamethasone. Molecular docking studies were conducted for compound 6b to investigate its mode of interaction within the binding site of both c-Met and VEGFR2 kinases." @default.
• W3044966413 created "2020-07-29" @default.
• W3044966413 creator A5007843479 @default.
• W3044966413 creator A5017894996 @default.
• W3044966413 creator A5059643071 @default.
• W3044966413 creator A5070924066 @default.
• W3044966413 creator A5081593043 @default.
• W3044966413 creator A5084843366 @default.
• W3044966413 creator A5089714271 @default.
• W3044966413 date "2020-07-24" @default.
• W3044966413 modified "2023-10-17" @default.
• W3044966413 title "Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors" @default.
• W3044966413 cites W1581429301 @default.
• W3044966413 cites W1583279678 @default.
• W3044966413 cites W1967398178 @default.
• W3044966413 cites W1974218564 @default.
• W3044966413 cites W1975223905 @default.
• W3044966413 cites W2000292756 @default.
• W3044966413 cites W2018431694 @default.
• W3044966413 cites W2022305202 @default.
• W3044966413 cites W2039155298 @default.
• W3044966413 cites W2059577406 @default.
• W3044966413 cites W2063544208 @default.
• W3044966413 cites W2068207881 @default.
• W3044966413 cites W2080251114 @default.
• W3044966413 cites W2086619383 @default.
• W3044966413 cites W2094234842 @default.
• W3044966413 cites W2095148711 @default.
• W3044966413 cites W2096844786 @default.
• W3044966413 cites W2102053414 @default.
• W3044966413 cites W2120460652 @default.
• W3044966413 cites W2136390065 @default.
• W3044966413 cites W2138309116 @default.
• W3044966413 cites W2138896702 @default.
• W3044966413 cites W2142656868 @default.
• W3044966413 cites W2156944722 @default.
• W3044966413 cites W2158144218 @default.
• W3044966413 cites W2170285778 @default.
• W3044966413 cites W2221511591 @default.
• W3044966413 cites W2230488900 @default.
• W3044966413 cites W2316020271 @default.
• W3044966413 cites W2318573979 @default.
• W3044966413 cites W2328212946 @default.
• W3044966413 cites W2342165340 @default.
• W3044966413 cites W2464352601 @default.
• W3044966413 cites W2604845232 @default.
• W3044966413 cites W2765240956 @default.
• W3044966413 cites W2789037080 @default.
• W3044966413 cites W2792389705 @default.
• W3044966413 cites W2793569353 @default.
• W3044966413 cites W2795353688 @default.
• W3044966413 cites W2892277437 @default.
• W3044966413 cites W2895231761 @default.
• W3044966413 cites W2898675269 @default.
• W3044966413 cites W2900605906 @default.
• W3044966413 cites W2910174043 @default.
• W3044966413 cites W2939564294 @default.
• W3044966413 cites W2950378123 @default.
• W3044966413 cites W3003183127 @default.
• W3044966413 cites W4250428608 @default.
• W3044966413 cites W856882514 @default.
• W3044966413 doi "https://doi.org/10.1021/acsomega.0c02038" @default.
• W3044966413 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7408256" @default.
• W3044966413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32775889" @default.
• W3044966413 hasPublicationYear "2020" @default.
• W3044966413 type Work @default.
• W3044966413 sameAs 3044966413 @default.
• W3044966413 citedByCount "17" @default.
• W3044966413 countsByYear W30449664132021 @default.
• W3044966413 countsByYear W30449664132022 @default.
• W3044966413 countsByYear W30449664132023 @default.
• W3044966413 crossrefType "journal-article" @default.
• W3044966413 hasAuthorship W3044966413A5007843479 @default.
• W3044966413 hasAuthorship W3044966413A5017894996 @default.
• W3044966413 hasAuthorship W3044966413A5059643071 @default.
• W3044966413 hasAuthorship W3044966413A5070924066 @default.
• W3044966413 hasAuthorship W3044966413A5081593043 @default.
• W3044966413 hasAuthorship W3044966413A5084843366 @default.
• W3044966413 hasAuthorship W3044966413A5089714271 @default.
• W3044966413 hasBestOaLocation W30449664131 @default.
• W3044966413 hasConcept C101544691 @default.
• W3044966413 hasConcept C146285616 @default.
• W3044966413 hasConcept C14858245 @default.
• W3044966413 hasConcept C150903083 @default.
• W3044966413 hasConcept C159110408 @default.
• W3044966413 hasConcept C167734588 @default.
• W3044966413 hasConcept C170493617 @default.
• W3044966413 hasConcept C184235292 @default.
• W3044966413 hasConcept C185592680 @default.
• W3044966413 hasConcept C202751555 @default.
• W3044966413 hasConcept C207001950 @default.
• W3044966413 hasConcept C2777025900 @default.
• W3044966413 hasConcept C2780394083 @default.
• W3044966413 hasConcept C41685203 @default.
• W3044966413 hasConcept C42362537 @default.
• W3044966413 hasConcept C502942594 @default.
• W3044966413 hasConcept C55493867 @default.
• W3044966413 hasConcept C57992300 @default.

• next